首页 > 最新文献

Expert Review of Ophthalmology最新文献

英文 中文
The utility of optical coherence tomography angiography in the management of neovascular age-related macular degeneration – current perspective 光学相干断层扫描血管造影术在治疗新生血管性年龄相关性黄斑变性中的应用——当前观点
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-03-04 DOI: 10.1080/17469899.2022.2084073
R. Schwartz, Nicola Cronbach, H. Madi, R. Reynolds, U. Chakravarthy
Optical coherence tomography angiography (OCTA) is a relatively new imaging modality that allows visualization of the retinal and choroidal vasculature. While this has traditionally only been possible through dye-based imaging techniques (fluorescein angiography (FA) and indocyanine green angiography (ICG)), OCTA offers a fast and noninvasive alternative that is readily repeatable and can be used to image the retinal and choroidal vasculature in a single scan without the need for dye injection. Another advantage of OCTA is its ability to produce depthresolved evaluation of the reflectance data from retinal tissue, providing a three-dimensional volume of information. The retinal and choroidal capillary networks are arranged into morphologically distinct layers, from the superficial capillary plexus to the choroid. In the case of neovascular age-related macular degeneration (nAMD), this enables the clinician to determine whether a neovascular network is present, its relative position within the retina/choroid and, with the use of repeated OCTA scans over multiple visits, whether this network is changing. However, there is currently no single standard for acquisition or interpretation of OCTA data. The first commercial OCTA machine (AngioVue, Optovue, Fremont, CA) was introduced in 2014 and was based on spectral domain OCT (SD-OCT). Subsequent OCTA devices have been based on either SD-OCT or swept source OCT (SS-OCT). SD-OCT and SS-OCT are both types of Fourier domain OCT but differ in their light source, wavelength, and photodetector, which results in differences in scanning speeds and resolution of imaging at the various levels within the retina and choroid. The longer wavelength of SS-OCT (~1050 nm, vs ~840 nm for SD-OCT) and reduced sensitivity rolloff enables acquisition of high-resolution OCTA imaging particularly of neovascular networks below the retinal pigment epithelium compared with SD-OCT scanning. The quicker scanning speeds of SS-OCT also allow for a larger area to be imaged. However, different devices utilize different algorithms to process and segment the data acquired, and therefore there are differences in the images produced. Continuous advances in OCTA technology and improvements in the quality of images produced have led to increasing use of OCTA globally for clinical purposes, particularly for the diagnosis and monitoring of macular neovascularization [1]. In this article, we discuss the role of OCTA in nAMD and how it can be of use to clinicians in the diagnosis and management of nAMD.
光学相干断层扫描血管造影术(OCTA)是一种相对较新的成像方式,可以对视网膜和脉络膜血管系统进行可视化。虽然传统上只有通过基于染料的成像技术(荧光素血管造影术(FA)和吲哚菁绿血管造影学(ICG))才能实现这一点,但OCTA提供了一种快速、无创的替代方案,易于重复,可用于在单次扫描中对视网膜和脉络膜血管系统成像,而无需注射染料。OCTA的另一个优点是它能够对视网膜组织的反射数据进行深度分辨评估,提供三维信息量。视网膜和脉络膜的毛细血管网从浅表毛细血管丛到脉络膜排列成形态上不同的层。在新生血管性年龄相关性黄斑变性(nAMD)的情况下,这使临床医生能够确定是否存在新生血管网络,其在视网膜/脉络膜内的相对位置,以及通过多次访问重复OCTA扫描,该网络是否正在改变。然而,目前没有单一的标准来获取或解释OCTA数据。第一台商用OCTA机器(AngioVue,Optovue,Fremont,CA)于2014年推出,基于频域OCT(SD-OCT)。后续OCTA装置基于SD-OCT或扫描源OCT(SS-OCT)。SD-OCT和SS-OCT都是傅立叶域OCT的类型,但它们的光源、波长和光电探测器不同,这导致视网膜和脉络膜内不同级别的扫描速度和成像分辨率不同。与SD-OCT扫描相比,SS-OCT的波长更长(约1050 nm,而SD-OCT的波长约840 nm)和灵敏度下降使得能够获得高分辨率OCTA成像,尤其是视网膜色素上皮下的新生血管网络。SS-OCT更快的扫描速度也允许对更大的区域进行成像。然而,不同的设备使用不同的算法来处理和分割所获取的数据,因此产生的图像存在差异。OCTA技术的不断进步和图像质量的提高导致OCTA在全球范围内越来越多地用于临床目的,特别是用于黄斑新生血管的诊断和监测[1]。在这篇文章中,我们讨论了OCTA在nAMD中的作用,以及它如何在nAMD的诊断和管理中对临床医生有用。
{"title":"The utility of optical coherence tomography angiography in the management of neovascular age-related macular degeneration – current perspective","authors":"R. Schwartz, Nicola Cronbach, H. Madi, R. Reynolds, U. Chakravarthy","doi":"10.1080/17469899.2022.2084073","DOIUrl":"https://doi.org/10.1080/17469899.2022.2084073","url":null,"abstract":"Optical coherence tomography angiography (OCTA) is a relatively new imaging modality that allows visualization of the retinal and choroidal vasculature. While this has traditionally only been possible through dye-based imaging techniques (fluorescein angiography (FA) and indocyanine green angiography (ICG)), OCTA offers a fast and noninvasive alternative that is readily repeatable and can be used to image the retinal and choroidal vasculature in a single scan without the need for dye injection. Another advantage of OCTA is its ability to produce depthresolved evaluation of the reflectance data from retinal tissue, providing a three-dimensional volume of information. The retinal and choroidal capillary networks are arranged into morphologically distinct layers, from the superficial capillary plexus to the choroid. In the case of neovascular age-related macular degeneration (nAMD), this enables the clinician to determine whether a neovascular network is present, its relative position within the retina/choroid and, with the use of repeated OCTA scans over multiple visits, whether this network is changing. However, there is currently no single standard for acquisition or interpretation of OCTA data. The first commercial OCTA machine (AngioVue, Optovue, Fremont, CA) was introduced in 2014 and was based on spectral domain OCT (SD-OCT). Subsequent OCTA devices have been based on either SD-OCT or swept source OCT (SS-OCT). SD-OCT and SS-OCT are both types of Fourier domain OCT but differ in their light source, wavelength, and photodetector, which results in differences in scanning speeds and resolution of imaging at the various levels within the retina and choroid. The longer wavelength of SS-OCT (~1050 nm, vs ~840 nm for SD-OCT) and reduced sensitivity rolloff enables acquisition of high-resolution OCTA imaging particularly of neovascular networks below the retinal pigment epithelium compared with SD-OCT scanning. The quicker scanning speeds of SS-OCT also allow for a larger area to be imaged. However, different devices utilize different algorithms to process and segment the data acquired, and therefore there are differences in the images produced. Continuous advances in OCTA technology and improvements in the quality of images produced have led to increasing use of OCTA globally for clinical purposes, particularly for the diagnosis and monitoring of macular neovascularization [1]. In this article, we discuss the role of OCTA in nAMD and how it can be of use to clinicians in the diagnosis and management of nAMD.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"81 - 85"},"PeriodicalIF":0.7,"publicationDate":"2022-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49363650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ophthalmic side effects of COVID-19 vaccines COVID-19疫苗的眼部副作用
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-03-04 DOI: 10.1080/17469899.2022.2066523
Bita Momenaei, Kasra Cheraqpour, M. Soleimani, S. Tabatabaei, M. Shahriari, Hamed Etesali, Ahmed Hussein, Yasaman Vaseghi, Bahareh Ramezani, A. Djalilian
ABSTRACT Introduction The COVID-19 pandemic has been a rapidly emerging global health concern since December 2019. Unprecedented efforts have been made to produce vaccines, which have proven to be successful. Areas covered This is a narrative review of the known ocular side effects related to the COVID-19 vaccines. Relevant literature was identified up to January 2022. Herein, reports of several side effects after immunization with COVID-19 vaccines, such as corneal graft rejection, ocular herpes simplex virus reactivation, scleritis, anterior and intermediate uveitis, multiple evanescent white dot syndrome, acute zonal occult outer retinopathy, panuveitis, multifocal choroiditis, toxoplasma retinochoroiditis, central serous retinopathy, branch/central retinal vein occlusion, paracentral acute middle maculopathy, arteritic anterior ischemic optic neuropathy, optic neuritis, third nerve palsy, superior ophthalmic vein thrombosis, and Tolosa–Hunt syndrome, are reviewed and presented. Expert opinion Our knowledge regarding vaccination-related adverse events during the COVID-19 pandemic is growing. Ocular side effects are very rare overall and can often be treatable and preventable. Vaccinations remain strongly recommended by experts due to their efficacy in decreasing the disease burden. It is of note that establishing a casual relationship between vaccines and side effects is not possible yet and the possibility of coincidence should be considered.
自2019年12月以来,COVID-19大流行已成为迅速出现的全球卫生问题。为生产疫苗作出了前所未有的努力,疫苗已被证明是成功的。本文是对已知与COVID-19疫苗相关的眼部副作用的叙述性综述。相关文献的检索截止到2022年1月。本文报道了COVID-19疫苗免疫后的几种副作用,如角膜移植排斥反应、眼部单纯疱疹病毒再激活、巩膜炎、前、中间葡萄膜炎、多发性消失性白点综合征、急性带状隐匿性外视网膜病变、全葡萄膜炎、多灶性脉络膜炎、弓形虫视网膜脉络膜炎、中枢性浆液性视网膜病变、视网膜分支/中央静脉闭塞、中央旁急性中黄斑病变、动脉前缺血性视神经病变、视神经炎,第三神经麻痹,眼上静脉血栓形成,和托洛萨-亨特综合征,回顾和介绍。我们对COVID-19大流行期间与疫苗接种相关的不良事件的了解正在增加。总的来说,眼部副作用非常罕见,通常是可以治疗和预防的。专家们仍然强烈建议接种疫苗,因为它们能有效地减轻疾病负担。值得注意的是,目前还不可能在疫苗和副作用之间建立偶然的关系,应考虑巧合的可能性。
{"title":"Ophthalmic side effects of COVID-19 vaccines","authors":"Bita Momenaei, Kasra Cheraqpour, M. Soleimani, S. Tabatabaei, M. Shahriari, Hamed Etesali, Ahmed Hussein, Yasaman Vaseghi, Bahareh Ramezani, A. Djalilian","doi":"10.1080/17469899.2022.2066523","DOIUrl":"https://doi.org/10.1080/17469899.2022.2066523","url":null,"abstract":"ABSTRACT Introduction The COVID-19 pandemic has been a rapidly emerging global health concern since December 2019. Unprecedented efforts have been made to produce vaccines, which have proven to be successful. Areas covered This is a narrative review of the known ocular side effects related to the COVID-19 vaccines. Relevant literature was identified up to January 2022. Herein, reports of several side effects after immunization with COVID-19 vaccines, such as corneal graft rejection, ocular herpes simplex virus reactivation, scleritis, anterior and intermediate uveitis, multiple evanescent white dot syndrome, acute zonal occult outer retinopathy, panuveitis, multifocal choroiditis, toxoplasma retinochoroiditis, central serous retinopathy, branch/central retinal vein occlusion, paracentral acute middle maculopathy, arteritic anterior ischemic optic neuropathy, optic neuritis, third nerve palsy, superior ophthalmic vein thrombosis, and Tolosa–Hunt syndrome, are reviewed and presented. Expert opinion Our knowledge regarding vaccination-related adverse events during the COVID-19 pandemic is growing. Ocular side effects are very rare overall and can often be treatable and preventable. Vaccinations remain strongly recommended by experts due to their efficacy in decreasing the disease burden. It is of note that establishing a casual relationship between vaccines and side effects is not possible yet and the possibility of coincidence should be considered.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"129 - 143"},"PeriodicalIF":0.7,"publicationDate":"2022-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45765987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Baseball-related ocular injuries in the United States: a 10-year analysis 美国棒球相关眼部损伤:一项10年分析
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-02-07 DOI: 10.1080/17469899.2022.2039629
P. Patel, Rhea Gopali, Anvith Reddy, Kajol K. Patel
ABSTRACT Background To analyze the incidence of baseball-related ocular injuries, mechanisms commonly associated with precipitating trauma, and secondary visual sequelae, and explore the age and sex-specific variations in the distributions of these variables. Methods Baseball-related ocular injuries presenting to the emergency department (ED) were identified using the National Electronic Injury Surveillance System for 2011 through 2020. Age, sex, diagnosis, mechanism of injury, visual sequela, and patient disposition were analyzed. Statistical comparisons were performed using the chi-square test and Fisher exact test. Results 558 ED presentations were captured, translating to an average national incidence of 1,492 events. The incidence of trauma declined notably. Most encounters involved pediatric (≤18) and male patients (82.6% and 87.6%, respectively). Patients commonly presented with contusions or abrasions (41.4%). Contact with the baseball was the most frequently mentioned mechanism of injury (87.6%). There was a significant age-related (P = 0.009) difference in the distributions of diagnoses. 7.3% of patients had a visual sequela. Conclusions There was a declining incidence of baseball-related ocular injuries presenting to the ED. However, the long-term complications of injuries could not be explored. Further efforts are required to understand the implications of ocular injuries to ensure patients receive appropriate protections.
背景:分析棒球相关眼部损伤的发生率、诱发损伤的机制以及继发性视觉后遗症,并探讨这些变量分布的年龄和性别差异。方法使用2011年至2020年的国家电子损伤监测系统对急诊部门(ED)的棒球相关眼部损伤进行识别。分析患者的年龄、性别、诊断、损伤机制、视觉后遗症及性格。采用卡方检验和Fisher精确检验进行统计学比较。结果558例ED报告被捕获,转化为全国平均1492例事件。创伤发生率明显下降。大多数患者为儿童(≤18岁)和男性(分别为82.6%和87.6%)。患者多表现为挫伤或擦伤(41.4%)。与棒球接触是最常见的损伤机制(87.6%)。诊断分布有显著的年龄相关差异(P = 0.009)。7.3%的患者有视觉后遗症。结论棒球相关眼部损伤在急诊科的发生率呈下降趋势,但损伤的长期并发症尚不清楚。需要进一步努力了解眼损伤的影响,以确保患者得到适当的保护。
{"title":"Baseball-related ocular injuries in the United States: a 10-year analysis","authors":"P. Patel, Rhea Gopali, Anvith Reddy, Kajol K. Patel","doi":"10.1080/17469899.2022.2039629","DOIUrl":"https://doi.org/10.1080/17469899.2022.2039629","url":null,"abstract":"ABSTRACT Background To analyze the incidence of baseball-related ocular injuries, mechanisms commonly associated with precipitating trauma, and secondary visual sequelae, and explore the age and sex-specific variations in the distributions of these variables. Methods Baseball-related ocular injuries presenting to the emergency department (ED) were identified using the National Electronic Injury Surveillance System for 2011 through 2020. Age, sex, diagnosis, mechanism of injury, visual sequela, and patient disposition were analyzed. Statistical comparisons were performed using the chi-square test and Fisher exact test. Results 558 ED presentations were captured, translating to an average national incidence of 1,492 events. The incidence of trauma declined notably. Most encounters involved pediatric (≤18) and male patients (82.6% and 87.6%, respectively). Patients commonly presented with contusions or abrasions (41.4%). Contact with the baseball was the most frequently mentioned mechanism of injury (87.6%). There was a significant age-related (P = 0.009) difference in the distributions of diagnoses. 7.3% of patients had a visual sequela. Conclusions There was a declining incidence of baseball-related ocular injuries presenting to the ED. However, the long-term complications of injuries could not be explored. Further efforts are required to understand the implications of ocular injuries to ensure patients receive appropriate protections.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"145 - 151"},"PeriodicalIF":0.7,"publicationDate":"2022-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45822100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The current surgical management of refractory full-thickness macular holes 难治性全层黄斑裂孔的外科治疗现状
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-01-02 DOI: 10.1080/17469899.2022.2045951
T. Caporossi, M. Ripa, Lorenzo Governatori, Alessandra Scampoli, G. Gambini, Clara Rizzo, Raphael Kilian, S. Rizzo
ABSTRACT Introduction Despite the great advancements in full-thickness macular hole (FTMH)-surgery that we have witnessed in the last decade, refractory FTMHs still occur. Areas covered Refractory FTMHs may result from the clinical characteristics and conformation of the hole, or from poor intraoperative and postoperative management. Failure of pars plana vitrectomy (PPV) and internal limiting membrane (ILM) peeling represents a challenge for vitreoretinal surgeons, and the continuous proposal of new surgical techniques expresses the ongoing need for the optimal treatment of macular holes. We review the current management and surgical techniques for refractory macular holes, highlighting evidence from recent studies. Expert opinion Surgical techniques continue to improve in order to satisfy the demands for the best management of refractory macular holes.
摘要简介尽管我们在过去十年中目睹了全层黄斑裂孔(FTMH)手术的巨大进步,但难治性FTMH仍然存在。难治性FTMHs覆盖的区域可能是由于孔的临床特征和形态,或术中和术后管理不善造成的。平面部玻璃体切除术(PPV)和内界膜(ILM)剥离的失败对玻璃体视网膜外科医生来说是一个挑战,新手术技术的不断提出表达了对黄斑裂孔最佳治疗的持续需求。我们回顾了目前难治性黄斑裂孔的治疗和手术技术,强调了最近研究的证据。专家意见手术技术不断改进,以满足对难治性黄斑裂孔最佳管理的需求。
{"title":"The current surgical management of refractory full-thickness macular holes","authors":"T. Caporossi, M. Ripa, Lorenzo Governatori, Alessandra Scampoli, G. Gambini, Clara Rizzo, Raphael Kilian, S. Rizzo","doi":"10.1080/17469899.2022.2045951","DOIUrl":"https://doi.org/10.1080/17469899.2022.2045951","url":null,"abstract":"ABSTRACT Introduction Despite the great advancements in full-thickness macular hole (FTMH)-surgery that we have witnessed in the last decade, refractory FTMHs still occur. Areas covered Refractory FTMHs may result from the clinical characteristics and conformation of the hole, or from poor intraoperative and postoperative management. Failure of pars plana vitrectomy (PPV) and internal limiting membrane (ILM) peeling represents a challenge for vitreoretinal surgeons, and the continuous proposal of new surgical techniques expresses the ongoing need for the optimal treatment of macular holes. We review the current management and surgical techniques for refractory macular holes, highlighting evidence from recent studies. Expert opinion Surgical techniques continue to improve in order to satisfy the demands for the best management of refractory macular holes.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"25 - 36"},"PeriodicalIF":0.7,"publicationDate":"2022-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43969529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Donor scleral graft vs pericardial graft vs scleral flap in tube drainage covering: advantages and disadvantages 供体巩膜移植物、心包移植物和巩膜瓣在管引流覆盖中的优缺点
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-01-02 DOI: 10.1080/17469899.2022.2026217
Nisa Silva, J. Bollemeijer, André Ferreira, M. Menéres, H. Lemij
ABSTRACT Introduction Glaucoma drainage devices (GDD) have become very popular in the surgical management of patients with glaucoma. Areas covered One of the important steps in GDD surgery is the tube coverage, in order to avoid the occurrence of postoperative tube exposure which carries the risk of infectious endophthalmitis. Several patch graft materials or autologous scleral procedures have been proposed, of which the donor scleral graft, pericardial graft, and scleral flap are among the most frequently adopted. We aimed to provide a comprehensive review of the literature on this topic, with a focus on the material and characteristics, surgical technique, and advantages and disadvantages of each of these three common options. Expert opinion Both donor scleral grafts and scleral flaps provide a low and similar rate of postoperative tube exposure and low costs. The scleral flap procedure is readily available but may carry the risk of intraoperative complications and corneal issues related to scleral biomechanical changes. Pericardial grafts are associated with higher rates of graft thinning and tube exposure.
青光眼引流装置(GDD)在青光眼患者的外科治疗中非常流行。覆盖区域GDD手术的重要步骤之一是管覆盖,以避免术后管暴露的发生,从而带来感染性眼内炎的风险。已有几种膜片移植材料或自体巩膜手术被提出,其中最常采用的是供体巩膜移植、心包移植和巩膜瓣。我们的目的是对这一主题的文献进行全面的回顾,重点是材料和特征,手术技术,以及这三种常见选择的优缺点。专家意见供体巩膜移植物和巩膜瓣都提供了低且相似的术后管暴露率和低成本。巩膜瓣手术很容易获得,但可能存在术中并发症和与巩膜生物力学变化相关的角膜问题的风险。心包移植与较高的移植物变薄和导管暴露率相关。
{"title":"Donor scleral graft vs pericardial graft vs scleral flap in tube drainage covering: advantages and disadvantages","authors":"Nisa Silva, J. Bollemeijer, André Ferreira, M. Menéres, H. Lemij","doi":"10.1080/17469899.2022.2026217","DOIUrl":"https://doi.org/10.1080/17469899.2022.2026217","url":null,"abstract":"ABSTRACT Introduction Glaucoma drainage devices (GDD) have become very popular in the surgical management of patients with glaucoma. Areas covered One of the important steps in GDD surgery is the tube coverage, in order to avoid the occurrence of postoperative tube exposure which carries the risk of infectious endophthalmitis. Several patch graft materials or autologous scleral procedures have been proposed, of which the donor scleral graft, pericardial graft, and scleral flap are among the most frequently adopted. We aimed to provide a comprehensive review of the literature on this topic, with a focus on the material and characteristics, surgical technique, and advantages and disadvantages of each of these three common options. Expert opinion Both donor scleral grafts and scleral flaps provide a low and similar rate of postoperative tube exposure and low costs. The scleral flap procedure is readily available but may carry the risk of intraoperative complications and corneal issues related to scleral biomechanical changes. Pericardial grafts are associated with higher rates of graft thinning and tube exposure.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"1 - 10"},"PeriodicalIF":0.7,"publicationDate":"2022-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47180994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Newer therapeutic agents for retinal diseases 视网膜疾病的新治疗剂
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-01-02 DOI: 10.1080/17469899.2022.2030709
A. Markan, S. Neupane, R. Agrawal, Vishali Gupta
ABSTRACT Introduction Last few decades in medical retina have encountered significant development in the field of pharmacotherapy. With better understanding of molecular mechanisms and disease pathophysiology, alternate pathways are being targeted in various clinical trials. Areas covered In this review, a comprehensive list of newer therapeutic agents in various retinal conditions like diabetic macular edema (DME), age-related macular degeneration (ARMD), inherited retinal diseases (IRDs) and non-arteritic ischemic optic neuropathy (NAION) have been elucidated. The review highlights alternate pathways involved in pathogenesis of DME and ARMD, and gives a brief summary of several phase I and phase II trials targeting these pathways. The review also briefly highlights the advancements in the field of gene therapy, stem cell transplantation, neuro-protection and retinal implants in IRDs. Lastly, available treatment options for NAION have been discussed. Expert opinion Evidence based medicine has allowed researches and vision scientists to explore newer drugs and target alternate disease pathways. Promising results with initial clinical trials will pave the pathway for larger studies and allow clinicians to overcome treatment burden presently associated with available treatment options.
近几十年来,视网膜医学在药物治疗领域取得了重大进展。随着对分子机制和疾病病理生理学的更好理解,各种临床试验的目标是替代途径。在这篇综述中,全面列出了各种视网膜疾病的新药物,如糖尿病黄斑水肿(DME),年龄相关性黄斑变性(ARMD),遗传性视网膜疾病(IRDs)和非动脉缺血性视神经病变(NAION)。这篇综述强调了DME和ARMD发病机制中涉及的其他途径,并简要总结了针对这些途径的几个I期和II期试验。综述了基因治疗、干细胞移植、神经保护和视网膜植入等方面的研究进展。最后,讨论了NAION的可用治疗方案。专家意见循证医学使研究人员和视觉科学家能够探索新的药物和针对替代疾病途径。初步临床试验的有希望的结果将为更大规模的研究铺平道路,并使临床医生能够克服目前与现有治疗方案相关的治疗负担。
{"title":"Newer therapeutic agents for retinal diseases","authors":"A. Markan, S. Neupane, R. Agrawal, Vishali Gupta","doi":"10.1080/17469899.2022.2030709","DOIUrl":"https://doi.org/10.1080/17469899.2022.2030709","url":null,"abstract":"ABSTRACT Introduction Last few decades in medical retina have encountered significant development in the field of pharmacotherapy. With better understanding of molecular mechanisms and disease pathophysiology, alternate pathways are being targeted in various clinical trials. Areas covered In this review, a comprehensive list of newer therapeutic agents in various retinal conditions like diabetic macular edema (DME), age-related macular degeneration (ARMD), inherited retinal diseases (IRDs) and non-arteritic ischemic optic neuropathy (NAION) have been elucidated. The review highlights alternate pathways involved in pathogenesis of DME and ARMD, and gives a brief summary of several phase I and phase II trials targeting these pathways. The review also briefly highlights the advancements in the field of gene therapy, stem cell transplantation, neuro-protection and retinal implants in IRDs. Lastly, available treatment options for NAION have been discussed. Expert opinion Evidence based medicine has allowed researches and vision scientists to explore newer drugs and target alternate disease pathways. Promising results with initial clinical trials will pave the pathway for larger studies and allow clinicians to overcome treatment burden presently associated with available treatment options.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"37 - 51"},"PeriodicalIF":0.7,"publicationDate":"2022-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43072391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precision medicine and glaucoma management: how mathematical modeling and artificial intelligence help in clinical practice. 精准医学和青光眼管理:数学建模和人工智能如何帮助临床实践。
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-01-01 Epub Date: 2022-10-06 DOI: 10.1080/17469899.2022.2130249
G Guidoboni, R Nunez, J Keller, C Wikle, E L Robinson, A C Verticchio Vercellin, B Siesky, F Oddone, L Quaranta, B Wirostko, F Topouzis, C-Y Cheng, I Januleviciene, A Wegner, G Antman, C Jones, A Harris
Electrical Engineering Computer Science, University of Missouri, Columbia, MO, United States; Statistics, University of Missouri, Columbia, MO, United States; School of Social Work, University of Missouri System, Columbia, MO, United States; Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, United States; IRCCS Fondazione Bietti, Rome, Italy; Centro Oculistico Italiano, Brescia, Italy; Department of Ophthalmologyh, Moran Eye Center, Salt Lake City, UT, United States; Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece; Singapore Eye Research Institute, Singapore, Singapore; Eye Clinic, Lithuanian University of Health Sciences, Kaunas, Lithuania; Institute for Refractive and Ophthalmic Surgery, Zürich, Switzerland; Department of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel; Mathematics, University of Missouri, Columbia, MO, United States
{"title":"Precision medicine and glaucoma management: how mathematical modeling and artificial intelligence help in clinical practice.","authors":"G Guidoboni, R Nunez, J Keller, C Wikle, E L Robinson, A C Verticchio Vercellin, B Siesky, F Oddone, L Quaranta, B Wirostko, F Topouzis, C-Y Cheng, I Januleviciene, A Wegner, G Antman, C Jones, A Harris","doi":"10.1080/17469899.2022.2130249","DOIUrl":"10.1080/17469899.2022.2130249","url":null,"abstract":"Electrical Engineering Computer Science, University of Missouri, Columbia, MO, United States; Statistics, University of Missouri, Columbia, MO, United States; School of Social Work, University of Missouri System, Columbia, MO, United States; Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, United States; IRCCS Fondazione Bietti, Rome, Italy; Centro Oculistico Italiano, Brescia, Italy; Department of Ophthalmologyh, Moran Eye Center, Salt Lake City, UT, United States; Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece; Singapore Eye Research Institute, Singapore, Singapore; Eye Clinic, Lithuanian University of Health Sciences, Kaunas, Lithuania; Institute for Refractive and Ophthalmic Surgery, Zürich, Switzerland; Department of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel; Mathematics, University of Missouri, Columbia, MO, United States","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 5","pages":"299-301"},"PeriodicalIF":0.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762696/pdf/nihms-1857631.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10223959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Triamcinolone acetonide injectable suspension for suprachoroidal use in the treatment of macular edema associated with uveitis. 曲安奈德注射用脉络膜上混悬液治疗葡萄膜炎引起的黄斑水肿。
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2022-01-01 DOI: 10.1080/17469899.2022.2114456
Joanne Thomas, Lucas Kim, Thomas Albini, Steven Yeh

Introduction: Macular edema due to noninfectious uveitis is a sight-threatening complication that is routinely treated with corticosteroids. Triamcinolone acetonide injectable suspension for suprachoroidal use (Xipere) is an alternative treatment option for patients with non-infectious uveitis associated macular edema.

Areas covered: This review describes the recently FDA approved triamcinolone acetonide injectable suspension that can be injected into the suprachoroidal space. This physiological space is between the sclera and choroid. This allows for therapeutic targeting of the retina and choroid. This review highlights published clinical trials for this novel drug preparation.

Expert opinion: Suprachoroidal administration of triamcinolone acetonide has shown improvement in vision and inflammation in studies with non-infectious uveitis associated macular edema. This unique delivery method suggests the potential to decrease side effects of anterior segment exposure such as glaucoma and cataract, but head-to-head trials are needed for further study of safety and efficacy. Additionally, there are promising prospective studies underway for utilization of the suprachoroidal space for other diseases including macular degeneration, diabetic macular edema, and ocular tumors.

简介:非感染性葡萄膜炎引起的黄斑水肿是一种威胁视力的并发症,通常用皮质类固醇治疗。曲安奈德脉络膜上注射混悬液(Xipere™)是非感染性葡萄膜炎相关性黄斑水肿患者的另一种治疗选择。涵盖领域:本综述描述了最近FDA批准的可注射到脉络膜上间隙的曲安奈德注射混悬液。这个生理间隙位于巩膜和脉络膜之间。这允许治疗视网膜和脉络膜的靶向。本文综述了已发表的这种新型药物制剂的临床试验。专家意见:在非感染性葡萄膜炎相关黄斑水肿的研究中,曲安奈德在脉络膜上给予改善视力和炎症。这种独特的给药方式可能减少前段暴露的副作用,如青光眼和白内障,但需要进一步研究安全性和有效性的头对头试验。此外,关于利用脉络膜上间隙治疗黄斑变性、糖尿病性黄斑水肿和眼部肿瘤等其他疾病的前瞻性研究也在进行中。
{"title":"Triamcinolone acetonide injectable suspension for suprachoroidal use in the treatment of macular edema associated with uveitis.","authors":"Joanne Thomas,&nbsp;Lucas Kim,&nbsp;Thomas Albini,&nbsp;Steven Yeh","doi":"10.1080/17469899.2022.2114456","DOIUrl":"https://doi.org/10.1080/17469899.2022.2114456","url":null,"abstract":"<p><strong>Introduction: </strong>Macular edema due to noninfectious uveitis is a sight-threatening complication that is routinely treated with corticosteroids. Triamcinolone acetonide injectable suspension for suprachoroidal use (Xipere<sup>™</sup>) is an alternative treatment option for patients with non-infectious uveitis associated macular edema.</p><p><strong>Areas covered: </strong>This review describes the recently FDA approved triamcinolone acetonide injectable suspension that can be injected into the suprachoroidal space. This physiological space is between the sclera and choroid. This allows for therapeutic targeting of the retina and choroid. This review highlights published clinical trials for this novel drug preparation.</p><p><strong>Expert opinion: </strong>Suprachoroidal administration of triamcinolone acetonide has shown improvement in vision and inflammation in studies with non-infectious uveitis associated macular edema. This unique delivery method suggests the potential to decrease side effects of anterior segment exposure such as glaucoma and cataract, but head-to-head trials are needed for further study of safety and efficacy. Additionally, there are promising prospective studies underway for utilization of the suprachoroidal space for other diseases including macular degeneration, diabetic macular edema, and ocular tumors.</p>","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 3","pages":"165-173"},"PeriodicalIF":0.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438525/pdf/nihms-1832307.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10042716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Hyalocyte origin, structure, and imaging. 透明细胞的起源、结构和成像。
IF 0.9 Q4 OPHTHALMOLOGY Pub Date : 2022-01-01 Epub Date: 2022-09-06 DOI: 10.1080/17469899.2022.2100762
Peter Wieghofer, Michael Engelbert, Toco Yp Chui, Richard B Rosen, Taiji Sakamoto, J Sebag

Introduction: Hyalocytes have been recognized as resident tissue macrophages of the vitreous body since the mid-19th century. Despite this, knowledge about their origin, turnover, and dynamics is limited.

Areas covered: Historically, initial studies on the origin of hyalocytes used light and electron microscopy. Modern investigations across species including rodents and humans will be described. Novel imaging is now available to study human hyalocytes in vivo. The shared ontogeny with retinal microglia and their eventual interdependence as well as differences will be discussed.

Expert opinion: Owing to a common origin as myeloid cells, hyalocytes and retinal microglia have similarities, but hyalocytes appear to be distinct as resident macrophages of the vitreous body.

引言自 19 世纪中叶以来,透明质细胞就被认为是玻璃体内的常驻组织巨噬细胞。尽管如此,人们对其起源、周转和动态的了解仍然有限:从历史上看,对透明细胞起源的最初研究使用的是光镜和电子显微镜。将介绍包括啮齿动物和人类在内的不同物种的现代研究。新的成像技术现在可用于研究体内的人类透明细胞。将讨论透明细胞与视网膜小胶质细胞的共同本体,以及它们最终的相互依存和差异:专家观点:由于共同起源于髓系细胞,透明质细胞和视网膜小胶质细胞有相似之处,但透明质细胞作为玻璃体内的常驻巨噬细胞似乎是与众不同的。
{"title":"Hyalocyte origin, structure, and imaging.","authors":"Peter Wieghofer, Michael Engelbert, Toco Yp Chui, Richard B Rosen, Taiji Sakamoto, J Sebag","doi":"10.1080/17469899.2022.2100762","DOIUrl":"10.1080/17469899.2022.2100762","url":null,"abstract":"<p><strong>Introduction: </strong>Hyalocytes have been recognized as resident tissue macrophages of the vitreous body since the mid-19<sup>th</sup> century. Despite this, knowledge about their origin, turnover, and dynamics is limited.</p><p><strong>Areas covered: </strong>Historically, initial studies on the origin of hyalocytes used light and electron microscopy. Modern investigations across species including rodents and humans will be described. Novel imaging is now available to study human hyalocytes <i>in vivo.</i> The shared ontogeny with retinal microglia and their eventual interdependence as well as differences will be discussed.</p><p><strong>Expert opinion: </strong>Owing to a common origin as myeloid cells, hyalocytes and retinal microglia have similarities, but hyalocytes appear to be distinct as resident macrophages of the vitreous body.</p>","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 4","pages":"233-248"},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831111/pdf/nihms-1823650.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10524385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polychromatic through-focus image quality in a wavefront-shaping presbyopia correcting intraocular lens 波前成形老花眼校正人工晶状体中的多色透焦图像质量
IF 0.7 Q4 OPHTHALMOLOGY Pub Date : 2021-12-21 DOI: 10.1080/17469899.2022.2021878
F. Pastor-Pascual, Alicia Gómez-Gómez, R. Montés-Micó, Ramón Ruiz-Mesa, Pedro Tañá-Rivero
ABSTRACT Objectives To compute the polychromatic through-focus image quality in eyes implanted with a new extended depth of focus (EDOF) intraocular lens (IOL). Methods Eight eyes of four patients who underwent implantation with the AcrySof IQ Vivity EDOF IOL were analyzed. Wavefront aberrations were measured. The optical metric for the polychromatic through-focus image quality used was the Visual Strehl ratio computed in the spatial domain (VSX). Eight eyes implanted with a monofocal IOL were also examined. Results The normalized VSX values change with vergence for both group of IOLs. However, the depth-of-focus (DoF) for the Vivity IOL was about 0.75, 1.00, and 1.25 D larger than the monofocal IOL, for 0.1, 0.2, and 0.3 logMAR visual acuities. The DoF computed from the polychromatic through-focus image quality for the Vivity IOL was about 2.50D, being this value 1.25D wider than the monofocal one. The DoF obtained from the defocus curve was about 2.25 D for eyes implanted with the Vivity IOL. Conclusions Polychromatic through-focus image quality analysis agrees with the clinical outcomes indicating that this methodology may be useful to estimate the DoF and the expected quality of vision in patients implanted with lenses from wavefront aberration measurement. This approach shows the increased DoF of the EDOF lens compared to a monofocal.
【摘要】目的计算新型扩展焦深人工晶状体(IOL)植入眼后的多色透焦图像质量。方法对4例8眼人工晶状体植入术患者进行分析。测量了波前像差。使用的多色透焦图像质量的光学度量是在空间域中计算的视觉施特赖比(VSX)。8只植入单焦点人工晶体的眼睛也进行了检查。结果两组人工晶状体的归一化VSX值随晶状体会聚而变化。然而,对于0.1、0.2和0.3 logMAR的视力,活体人工晶状体的焦深(DoF)比单焦点人工晶状体大0.75、1.00和1.25 D。Vivity IOL的多色透焦图像质量计算的DoF约为2.50D,该值比单焦图像质量宽1.25D。活体人工晶状体离焦曲线的DoF约为2.25 D。结论多色透焦图像质量分析结果与临床结果一致,表明该方法可用于通过波前像差测量来估计人工晶状体植入术患者的DoF和预期视力质量。这种方法表明,与单焦点相比,EDOF镜头的DoF增加了。
{"title":"Polychromatic through-focus image quality in a wavefront-shaping presbyopia correcting intraocular lens","authors":"F. Pastor-Pascual, Alicia Gómez-Gómez, R. Montés-Micó, Ramón Ruiz-Mesa, Pedro Tañá-Rivero","doi":"10.1080/17469899.2022.2021878","DOIUrl":"https://doi.org/10.1080/17469899.2022.2021878","url":null,"abstract":"ABSTRACT Objectives To compute the polychromatic through-focus image quality in eyes implanted with a new extended depth of focus (EDOF) intraocular lens (IOL). Methods Eight eyes of four patients who underwent implantation with the AcrySof IQ Vivity EDOF IOL were analyzed. Wavefront aberrations were measured. The optical metric for the polychromatic through-focus image quality used was the Visual Strehl ratio computed in the spatial domain (VSX). Eight eyes implanted with a monofocal IOL were also examined. Results The normalized VSX values change with vergence for both group of IOLs. However, the depth-of-focus (DoF) for the Vivity IOL was about 0.75, 1.00, and 1.25 D larger than the monofocal IOL, for 0.1, 0.2, and 0.3 logMAR visual acuities. The DoF computed from the polychromatic through-focus image quality for the Vivity IOL was about 2.50D, being this value 1.25D wider than the monofocal one. The DoF obtained from the defocus curve was about 2.25 D for eyes implanted with the Vivity IOL. Conclusions Polychromatic through-focus image quality analysis agrees with the clinical outcomes indicating that this methodology may be useful to estimate the DoF and the expected quality of vision in patients implanted with lenses from wavefront aberration measurement. This approach shows the increased DoF of the EDOF lens compared to a monofocal.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"75 - 79"},"PeriodicalIF":0.7,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45732975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Expert Review of Ophthalmology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1